Answers are grounded in this paper and cite their sources.
Ewing sarcoma (EwS) is a rare pediatric cancer of the bone and soft tissue. Although the five-year survival rate of localized disease is relatively high, outcomes for patients with metastatic or recurrent disease are poor. Additionally, aggressive chemotherapy use in pediatric populations increases the risk of secondary complications. We have previously demonstrated the success of in vitro targeting of replication stress in EwS. Here, we evaluate this combination in vivo. Cell division cycle 7 (CDC7), also known as DBF4-dependent kinase (DDK), and WEE1 kinase inhibition was compared to EwS standard-of-care regimens. NSG mice received subcutaneous injections of the cell lines TC-32, A673, or RD-ES, or engraftments of SJEWS001321_X1 patient derived xenograft tissue, followed by three cycles of treatment. Arms with DDK inhibition (DDKi) + WEE1 inhibition + irinotecan (triplet arm) delivered with an optimized schedule were significantly more effective in acute reduction of tumor volume with durable reduction of volume compared to all other groups in TC-32 cell line derived xenografts (p < 0.01). Triplet arms with full dose or half dose irinotecan were equally effective (p > 0.05), suggesting that this strategy allows chemotherapeutic de-escalation. In an EwS patient derived xenograft, arms with DDKi + irinotecan were as effective as the triplet arm (p > 0.05). Replication stress targeted therapy with a chemotherapy backbone is more efficacious than comparable standard-of-care therapies and allows dose de-escalation of chemotherapy. Thus, this strategy is a promising potential therapeutic combination in Ewing sarcoma and should be considered for advancement to the clinic.
No takes yet. Share an insight, caveat, or question.
Isenhart et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: